ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01859026
Recruitment Status : Recruiting
First Posted : May 21, 2013
Last Update Posted : May 14, 2018
Sponsor:
Collaborator:
Array BioPharma
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 31, 2019
  Estimated Study Completion Date : March 31, 2020